IOSP trades 14.5% below Wall Street's consensus target of $110.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IOSP achieves its forward estimates and maintains a stable P/E multiple of 19.5x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, Innospec Inc. (IOSP) has a Wall Street consensus price target of $110.00, based on estimates from 9 covering analysts. With the stock currently trading at $96.08, this represents a potential upside of +14.5%. The company has a market capitalization of $2.37B.
Analyst price targets range from a low of $110.00 to a high of $110.00, representing a 0% spread in expectations. The median target of $110.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IOSP trades at a trailing P/E of 20.6x and forward P/E of 19.5x. The forward PEG ratio of 0.61 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +0.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $89.33, with bear and bull scenarios of $56.28 and $117.70 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HWKNHawkins, Inc. | $2.6B | $124.55 | $142.00 | +14.0% | Buy | 31.7x | 2 |
 BCPCBalchem Corp | $5.4B | $168.40 | $215.00 | +27.7% | Buy | 31.2x | 10 |
 ITICInvestors Title Company | $553M | $292.86 | — | — | — | 48.1x | — |
 KWRQuaker Houghton | $2.8B | $159.47 | $182.50 | +14.4% | Buy | 20.3x | 15 |
 CBTCabot Corp. | $4.1B | $79.47 | $94.00 | +18.3% | Buy | 12.5x | 15 |
 ASIXAdvanSix Inc. | $451M | $16.72 | $30.80 | +84.2% | Buy | 90.4x | 6 |
 ALBAlbemarle Corporation | $13.8B | $116.80 | $202.63 | +73.5% | Buy | 10.2x | 45 |
 ECLEcolab Inc. | $77.7B | $276.22 | $326.13 | +18.1% | Buy | 33.9x | 37 |
 IFFInternational Flavors & Fragrances Inc. | $21.9B | $85.79 | $95.00 | +10.7% | Buy | 24.9x | 34 |
 TROXTronox Holdings plc | $702M | $4.40 | $8.08 | +83.6% | Buy | — | 17 |
Quick answers to the most common questions about buying IOSP stock.
Innospec Inc. (IOSP) has a consensus 12-month price target of $110, implying 14.5% upside from $96.08. The 9 analysts covering IOSP see moderate appreciation potential.
IOSP has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $110 implies 14.5% upside from current levels.
With a forward P/E of 19.4624x, IOSP trades at a relatively low valuation. The consensus target of $110 implies 14.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $110 for IOSP, while the most conservative target is $110. The consensus of $110 represents the median expectation. Our quantitative valuation model projects a bull case target of $118 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IOSP is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IOSP stock forecast based on 9 Wall Street analysts shows a consensus price target of $110, with estimates ranging from $110 (bear case) to $110 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $89, with bear/bull scenarios of $56/$118.
Our quantitative valuation model calculates IOSP's fair value at $89 (base case), with a bear case of $56 and bull case of $118. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
IOSP trades at a forward P/E ratio of 19.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on IOSP, with a "Hold" consensus rating and $110 price target (14.5% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IOSP analyst price targets range from $110 to $110, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $110 consensus represents the middle ground. Our model's $56-$118 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.